Review
Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit
- PMID: 23185844
Item in Clipboard
Review
Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit
Prescrire Int.
2012 Oct.
Abstract
In a placebo-controlled trial, the median time to radiologic documentation of cancer worsening or death was extended by about 6 months, although patients experienced many, often serious, adverse effects.
Similar articles
-
Role of everolimus in pancreatic neuroendocrine tumors.Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Expert Rev Anticancer Ther. 2011. PMID: 21932937 Review.
-
Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Ann Pharmacother. 2012. PMID: 22947595 Review.
-
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Adv Ther. 2010. PMID: 20623346 Review.
-
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.Anticancer Res. 2016 Feb;36(2):713-9. Anticancer Res. 2016. PMID: 26851029 Free PMC article. Clinical Trial.
-
Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. N Engl J Med. 2011. PMID: 21306238 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous